BioIVT Acquires XenoTech from Sekisui Chemical
September 12, 2022
BioIVT has acquired XenoTech, a Kansas City–based provider of ADME‑Tox in vitro models and contract research services, from Sekisui Chemical. The acquisition expands BioIVT's hepatic product portfolio and ADME/DMPK capabilities to better support biopharma customers' preclinical testing needs. Financial terms were not disclosed.
- Buyers
- BioIVT
- Targets
- XenoTech
- Sellers
- Sekisui Chemical
- Industry
- Biotechnology
- Location
- Kansas, United States
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.